Message Font: Serif | Sans-Serif
No. of Recommendations: 0
Alnylam Presents Initial 2017 Pipeline Goals at R&D Day with Focus on Alnylam 2020 Strategy
Dec. 16, 2016 7:05 a.m. ET
-- Three Mid- to Late-Stage Programs Advancing Toward Potential Commercialization --

-- In Addition, Company Announces Positive Preliminary Results from

Phase 1 Study of ALN-TTRsc02 --

CAMBRIDGE, Mass.--(BUSINESS WIRE)--December 16, 2016--
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting its R&D Day in New York City today. During the event, the Company will discuss its pipeline goals for 2017, focusing primarily on three mid- to late-stage programs advancing toward potential commercialization and on the path to achieving its Alnylam 2020 goals. The highlighted programs, all of which are expected to be in Phase 3 trials or in registration in 2017, include patisiran in development for the treatment of hereditary ATTR amyloidosis (hATTR) with polyneuropathy, fitusiran in development for the treatment of hemophilia and rare bleeding disorders, and givosiran (formerly ALN-AS1) in development for the treatment of acute hepatic porphyrias. Alnylam believes that all three investigational RNAi therapeutics have the potential to become transformative medicines for patients afflicted with these rare and ultra-rare orphan diseases with high unmet medical need. In addition, Alnylam will present preliminary positive Phase 1 study results for ALN-TTRsc02, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis.

"In the coming year, we look forward to the advancement of our mid- to late-stage pipeline and the continued evolution of our organization, as we prepare to make the planned transition from a development-stage company toward a multi-product, commercial-stage biopharmaceutical company," said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. "As we near 2020, we continue to be focused on pipeline execution and the building of capabilities that we believe will enable us to achieve our Alnylam 2020 goals, bringing RNAi therapeutics to patients in need around the world."

2017 Pipeline Goals

Patisiran, an investigational RNAi therapeutic in development for the treatment of hATTR with polyneuropathy. Alnylam plans to:

-- Complete APOLLO Phase 3 study in 2017.

-- The Company expects to report top-line data from the APOLLO Phase
3 trial in mid-2017 and additional results in late 2017.

-- Assuming positive Phase 3 data, Alnylam plans to submit a New Drug
Application (NDA) and Marketing Authorisation Application (MAA)
for patisiran at year-end 2017.

-- Present 36-month data from patients originally enrolled in the patisiran
Phase 2 Open-Label Extension (OLE) study in late 2017.
Fitusiran, an investigational RNAi therapeutic for the treatment of hemophilia and rare bleeding disorders. Alnylam plans to:

-- Initiate the ATLAS Phase 3 program in early 2017.

-- The ATLAS program is expected to consist of three separate Phase 3
trials: ATLAS-INH in severe hemophilia A and B patients with
inhibitors; ATLAS-A/B in severe hemophilia A and B patients
without inhibitors; and, ATLAS-PPX in severe hemophilia A and B
patients with or without inhibitors, switching from prophylactic
factor or bypassing agent therapy to fitusiran prophylaxis.

-- Present data from ongoing fitusiran trials in mid- and late 2017.

Givosiran, an investigational RNAi therapeutic for the treatment of acute hepatic porphyrias. Alnylam plans to:

-- Present additional data from the ongoing randomized, double-blind,
placebo-controlled Phase 1, Part C study in recurrent attack acute
intermittent porphyria (AIP) patients in mid-2017.

-- Initiate a givosiran Phase 3 trial in late 2017.
Alnylam also plans to continue support of The Medicines Company's advancement of inclisiran (formerly ALN-PCSsc) into Phase 3 studies in early and mid-2017. In addition, the Company plans to continue advancement of its earlier-stage clinical pipeline programs with multiple data read-outs expected throughout 2017.

ALN-TTRsc02 Preliminary Phase 1 Data

The Company also announced preliminary clinical data from its Phase 1 study of ALN-TTRsc02, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis. The Phase 1 trial is a randomized, placebo-controlled, single ascending-dose study in healthy volunteers receiving fixed subcutaneous doses ranging from 5 mg to 300 mg.

New results (N=48) showed:

-- Single subcutaneous doses of ALN-TTRsc02 achieved robust transthyretin
(TTR) knockdown of up to 98.4 percent (mean max of 97.1 +/- 0.5 percent),
with durability for well over four months. At a dose of 50 mg,
ALN-TTRsc02 achieved a mean knockdown at day 90 of 86.2%. Based on these
results, the Company believes that a once-quarterly, fixed dose of 25 to
50 mg of ALN-TTRsc02 could achieve clamped and potentially clinically
meaningful reductions exceeding 80% of TTR, the disease-causing protein
in hATTR amyloidosis.

-- In addition, ALN-TTRsc02 was generally well tolerated in healthy
volunteers, with no serious adverse events and no discontinuations due to
adverse events. All adverse events reported were mild or moderate in
severity and included transient injection site reactions (redness and
pain), pruritus, cough, nausea, fatigue and abdominal pain. No
significant changes were reported in hematologic or laboratory parameters
(e.g., liver function tests), vital signs or physical exams.
"At Alnylam, we remain committed to the goal of bringing RNAi therapeutics to hATTR amyloidosis patients. We are encouraged by these initial results from ALN-TTRsc02 and the broader advances of our Enhanced Stabilization Chemistry (ESC) platform that have enabled an over 100-fold improvement of potency and a meaningful improvement in durability in our GalNAc-siRNA conjugate efforts," said Eric Green, Vice President, General Manager of the TTR Program. "Pending positive results from the APOLLO Phase 3 study of patisiran, we plan to engage regulators to align on a development path for ALN-TTRsc02. With potent TTR knockdown and durability supportive of once-quarterly dosing, we believe ALN-TTRsc02 has the potential to be a best-in-class therapeutic for patients with all forms of ATTR amyloidosis."

Sanofi Genzyme Alliance

In January 2014, Alnylam and Sanofi Genzyme, the specialty care global business unit of Sanofi, formed an alliance to accelerate and expand the development and commercialization of RNAi therapeutics across the world. The alliance is structured as a multi-product geographic alliance in the field of rare diseases. Alnylam retains product rights in the United States, Canada and Western Europe, while Sanofi Genzyme obtained the right to access certain programs in Alnylam's current and future Genetic Medicines pipeline in the rest of the world (ROW) through the end of 2019, together with certain broader co-development/co-commercialization rights and global rights for certain products. In the case of patisiran, Alnylam will advance the product in the United States, Canada and Western Europe, while Sanofi Genzyme will advance the product in the ROW. In the case of fitusiran, Sanofi Genzyme has elected to opt in to co-develop (through Sanofi R&D) and co-commercialize fitusiran in the United States, Canada and Western Europe, in addition to developing and commercializing fitusiran in its ROW territories.

About RNAi

RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development. Its discovery has been heralded as "a major scientific breakthrough that happens once every decade or so," and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi is a natural process of gene silencing that occurs in organisms ranging from plants to mammals. By harnessing the natural biological process of RNAi occurring in our cells, the creation of a major new class of medicines, known as RNAi therapeutics, is on the horizon. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, target the cause of diseases by potently silencing specific mRNAs, thereby preventing disease-causing proteins from being made. RNAi therapeutics have the potential to treat disease and help patients in a fundamentally new way.
Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.